BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BIOSAFE's Sepax System Receives Chinese SFDA Approval


11/19/2012 6:53:43 AM

EYSINS, Switzerland, Nov. 19, 2012 /PRNewswire/ -- Biosafe Group SA, announced today that it has obtained Chinese SFDA registration for its Sepax(R) device, completing its worldwide registration program. Sepax is now available for immediate sale in China through Biosafe's recently established local subsidiary in Shanghai and is the first fully-automated cell separation system approved for use in the Chinese stem cell processing market.

http://photos.prnewswire.com/prnh/20121119/574143 )

Olivier Waridel, Chief Executive Officer of Biosafe, said "This is a major milestone for the Biosafe Group and we are pleased to offer our industry-leading products throughout the People's Republic of China. We look forward to contributing to developping its rapidly expanding cord blood banking, by providing state-of-the-art technology and premium service".

About the Biosafe Group

Founded in 1997, Biosafe Group SA, the world-leader in cell processing for stem cell banking and regenerative medicine applications, is active in design, manufacture and marketing of automated cell processing systems. Headquarted in Switzerland and privately-owned, Biosafe operates through four regional subsidiaries (Geneva, Houston, Hong-Kong and Shanghai) and is present in more than 45 countries, either directly or through distributors.

Biosafe's flagship Sepax cell separation technology is a versatile platform dedicated to adult stem cell processing, adressing major medical markets such as cord blood banking, stem cell transplantation and regenerative medicine. The Sepax system is used by the majority of public and family cord blood banks in the world, with more than 800 devices installed. Besides cord blood banks, Sepax is used in numerous translational medicine and point of care applications. Key advantages of Sepax patented technology are full automation, easy handling, a closed capability system, fast processing, stable and repeatable performance. Sepax technology is complemented by a number of accessories ranging from automated cryoprotectant delivery systems (Coolmix(R)) to an extensive single use article portfolio.

CONTACT:

Telephone: Biosafe Group Switzerland

Chris Bolton

CFO +41-22-365-2727

Email: christopher.bolton@biosafe.ch info@biosafe.ch

Biosafe China info@biosafeachina.com

Biosafe Asia-Pacific info@biosafeasiapacific.com

Biosafe North America: info@biosafeamerica.com

Website: http://www.biosafe.ch



Read at BioSpace.com

BIOSAFE
SFDA
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES